The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast Cancer

PloS One
Stefania GoriLuca Boni

Abstract

The management of pT1a-b pN0 HER2-positive breast cancer is controversial and no data about the efficacy of trastuzumab in this setting are available from randomized clinical trials. The aims of this retrospective study were to assess how patients are managed in clinical practice in Italy, which clinical or biological characteristics influenced the choice of adjuvant systemic therapy and the outcome of patients. Data of consecutive patients who underwent surgery from January 2007 to December 2012 for HER2-positive, pT1a-b pN0 M0 breast cancer were retrospectively collected from 28 Italian centres. Analysis of contingency tables and multivariate generalized logit models were used to investigate the association between the baseline clinical and biological features and the treatment strategy adopted. Among 303 enrolled patients, 204 received adjuvant systemic therapy with trastuzumab, 65 adjuvant systemic therapy without trastuzumab and 34 did not receive adjuvant systemic therapy. At the multivariate analysis age, tumor size, proliferation index and hormone receptor status were significantly associated with the treatment choice. Five-year disease-free survival (DFS) probability was 95%, 94.3% and 69.6% for patients treated with a...Continue Reading

References

Oct 21, 2005·The New England Journal of Medicine·Martine J Piccart-GebhartUNKNOWN Herceptin Adjuvant (HERA) Trial Study Team
Oct 21, 2005·The New England Journal of Medicine·Edward H RomondNorman Wolmark
Feb 24, 2006·The New England Journal of Medicine·Heikki JoensuuUNKNOWN FinHer Study Investigators
Jul 20, 2007·Annals of Surgical Oncology·Timothy KennedyDavid P Winchester
Nov 1, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Emer O HanrahanVicente Valero
Nov 4, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ana M Gonzalez-AnguloGabriel N Hortobagyi
Nov 4, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Giuseppe CuriglianoAron Goldhirsch
Nov 4, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Heikki JoensuuPirkko-Liisa Kellokumpu-Lehtinen
Nov 18, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Marc SpielmannFrédérique Penault-Llorca
Jun 10, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Marion ProcterMartine J Piccart-Gebhart
Jul 2, 2010·Journal of Oncology Practice·Stephen B Edge
Jun 18, 2011·International Journal of Clinical Oncology·Akiyo HorioHiroji Iwata
Oct 14, 2011·The New England Journal of Medicine·Dennis SlamonUNKNOWN Breast Cancer International Research Group
Nov 2, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Edith A PerezRobert B Jenkins
Oct 30, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M J RodriguesP H Cottu
Jan 9, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G HouvenaeghelB Esterni
Feb 12, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ines Vaz-LuisRachel A Freedman
Jun 4, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ines Vaz-LuisNancy U Lin
Oct 22, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Edith A PerezNorman Wolmark
Jan 8, 2015·The New England Journal of Medicine·Sara M TolaneyEric P Winer
Mar 1, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G HouvenaeghelB Esterni

❮ Previous
Next ❯

Citations

Feb 2, 2016·Cancer Treatment Reviews·Antonino MusolinoFrancesco Leonardi
Jul 1, 2016·Breast Cancer Research and Treatment·Mette S van RamshorstGabe S Sonke
Apr 12, 2017·Journal of Chemotherapy·Alberto RussiAngelo Claudio Palozzo

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy
dissection

Software Mentioned

SAS

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.